地诺单抗疗效如何？

Cancer is the enemy of human health. Although cancer can be cured in the early stages through some treatments, the probability of developing the disease in the early stages is not very high. Many patients often develop cancer tumors only in the late stages. For patients with advanced cancer, if treatment is not timely, it is very likely that the cancer cells will metastasize to distant places, among which bone metastasis is a common form of cancer metastasis. Fortunately, we have denosumab, an injectable drug that specifically treats cancer bone metastasis. How effective is denosumab?

Clinical data showed that compared with zoledronic acid, denosumab prolonged the time to the first adverse bone event (ARE) in patients by 17%, or significantly delayed the median time to the first bone-related event (SRE) by 8.2 months (27.6 months vs. 19.4 months). months), denosumab also extended the time interval from the first episode to the recurrence of SRE by 18% in the study; in addition, for patients with mild or no pain when enrolled in the study, compared with zoledronic acid, denosumab can also significantly extend the time interval between pain exacerbation, which shows that the therapeutic effect of denosumab is very good.

It can only be given by subcutaneous injection, not intravenous infusion, intramuscular infusion or intradermal injection. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.